These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 12660504

  • 1. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
    Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, Muiesan P, Rela M, Heaton ND, Mieli-Vergani G, Dhawan A.
    Transplantation; 2003 Mar 27; 75(6):796-9. PubMed ID: 12660504
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, Tan JM.
    Transpl Immunol; 2008 Jan 27; 18(3):281-5. PubMed ID: 18047938
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G.
    Transpl Int; 2005 Jan 27; 18(1):36-42. PubMed ID: 15612981
    [Abstract] [Full Text] [Related]

  • 8. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients.
    Oberholzer J, John E, Lumpaopong A, Testa G, Sankary HN, Briars L, Kraft KA, Knight PS, Verghese P, Benedetti E.
    Pediatr Transplant; 2005 Aug 27; 9(4):456-63. PubMed ID: 16048597
    [Abstract] [Full Text] [Related]

  • 9. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients.
    Ganschow R, Grabhorn E, Schulz A, Von Hugo A, Rogiers X, Burdelski M.
    Pediatr Transplant; 2005 Dec 27; 9(6):741-5. PubMed ID: 16269045
    [Abstract] [Full Text] [Related]

  • 10. Basiliximab treatment for steroid-resistant rejection in pediatric patients following liver transplantation for acute liver failure.
    Shigeta T, Sakamoto S, Uchida H, Sasaki K, Hamano I, Kanazawa H, Fukuda A, Kawai T, Onodera M, Nakazawa A, Kasahara M.
    Pediatr Transplant; 2014 Dec 27; 18(8):860-7. PubMed ID: 25311536
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
    Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO.
    Transpl Int; 2001 Dec 27; 14(6):396-404. PubMed ID: 11793037
    [Abstract] [Full Text] [Related]

  • 13. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
    Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, Wilkinson AH, Mulloy LL, Bourbigot BJ, Prestele H, Korn A, Girault D, Simulect International Study Group.
    Transplantation; 2003 Jan 15; 75(1):37-43. PubMed ID: 12544868
    [Abstract] [Full Text] [Related]

  • 14. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy el-M, Aghoneim M.
    Exp Clin Transplant; 2007 Dec 15; 5(2):673-9. PubMed ID: 18194120
    [Abstract] [Full Text] [Related]

  • 15. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients.
    Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, Lemire J, Crocker JF, Cochat P, Clark G, Chodoff L, Korn A, Hall M.
    Transplantation; 2002 Oct 15; 74(7):961-6. PubMed ID: 12394837
    [Abstract] [Full Text] [Related]

  • 16. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul 15; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients.
    Aw MM, Verma A, Rela M, Heaton N, Mieli-Vergani G, Dhawan A.
    Liver Transpl; 2008 Sep 15; 14(9):1303-8. PubMed ID: 18756458
    [Abstract] [Full Text] [Related]

  • 18. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
    Miura M, Harada H, Fukuzawa N, Iwami D, Taniguchi A, Seki T, Togashi M, Ogawa Y, Satoh H, Hirano T.
    Clin Transplant; 2005 Sep 15; 19 Suppl 14():54-8. PubMed ID: 15955170
    [Abstract] [Full Text] [Related]

  • 19. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group.
    N Engl J Med; 2006 Nov 09; 355(19):1967-77. PubMed ID: 17093248
    [Abstract] [Full Text] [Related]

  • 20. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.